<DOC>
	<DOCNO>NCT01001715</DOCNO>
	<brief_summary>Primary objective demonstrate activity REGN475/SAR164877 reduce pain associate vertebral fracture . Secondary objective : - ass safety tolerability REGN475/SAR164877 patient vertebral fracture pain ; - characterize pharmacokinetic immunogenicity profile REGN475/SAR164877 population .</brief_summary>
	<brief_title>Single Injection REGN475/SAR164877 Treatment Vertebral Fracture Pain</brief_title>
	<detailed_description>The duration study period participant 13 week , include screen period 5 day , 12-week follow-up injection .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Spinal Fractures</mesh_term>
	<criteria>Inclusion criterion : Moderate severe pain due nontraumatic vertebral fracture associate osteoporosis . Exclusion criterion : Mild pain score Pain IntensityNumeric Rating Scale [ PINRS ] screen randomization visit ; Narcotic addiction ; Postfracture vertebral instability ; Unwillingness use studydefined rescue analgesia exclusively . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>